<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605433</url>
  </required_header>
  <id_info>
    <org_study_id>SCOOP</org_study_id>
    <nct_id>NCT03605433</nct_id>
  </id_info>
  <brief_title>Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets</brief_title>
  <acronym>SCOOP</acronym>
  <official_title>Surgical Coronary Revascularization Outcomes After Oral Anticoagulation or Antiplatelet Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar e Universitário de Coimbra, E.P.E.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar e Universitário de Coimbra, E.P.E.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate whether treatment with oral anticoagulation
      or oral anticoagulation and aspirin is better than aspirin alone in cardiovascular outcomes
      and saphenous graft patency in patients submitted to coronary artery bypass graft.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to the first occurrence of either myocardial infarction, stroke, or cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Patency</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to the first occurence of saphenous graft oclusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to the first occurrence of major bleeding (modified International Society on Thrombosis and Haemostasis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE, cardiovascular death</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to first occurrence of either coronary heart disease death, myocardial infarction, ischemic stroke, acute limb ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomization to first occurrence of all-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Saphenous Vein Graft Patency</condition>
  <arm_group>
    <arm_group_label>Oral Anticoagulation+Antiplatelet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiplatet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation</description>
    <arm_group_label>Antiplatet</arm_group_label>
    <arm_group_label>Oral Anticoagulation</arm_group_label>
    <arm_group_label>Oral Anticoagulation+Antiplatelet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred to coronary artery bypass graft and at least one saphenous vein
             graft

        Exclusion Criteria:

          -  Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy or oral
             anticoagulant therapy

          -  Stroke within 1 month or any history of hemorrhagic or lacunar stroke

          -  Estimated glomerular filtration rate (eGFR)&lt;15 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis Paiva, MD</last_name>
    <phone>+351917952197</phone>
    <email>luisvpaiva@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 22, 2018</last_update_submitted>
  <last_update_submitted_qc>July 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar e Universitário de Coimbra, E.P.E.</investigator_affiliation>
    <investigator_full_name>Luís Paiva</investigator_full_name>
    <investigator_title>Luis Paiva</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

